4,7-Decanediol, 2,4,7,9-tetramethyl-

Genetic toxicity: in vitro

Administrative data

Endpoint:

in vitro gene mutation study in mammalian cells

Remarks:

Type of genotoxicity: gene mutation

Type of information:

migrated information: read-across based on grouping of substances (category approach)

Adequacy of study:

key study

Study period:

11.-23. August 2010

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: according to EC Directive 92/69/EEC and Regulation EC/440/2008 guideline methods under GLP conditions. This data valid as documented CCRF for this category (Acetylenic geminalic diols)

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2010

Report date:

2010

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)

GLP compliance:

yes

Type of assay:

mammalian cell gene mutation assay

Test material

Test material information

Constituent 1

Reference substance name:

2,4,7,9-tetramethyldec-5-yne-4,7-diol

EC Number:

204-809-1

EC Name:

2,4,7,9-tetramethyldec-5-yne-4,7-diol

Cas Number:

126-86-3

Molecular formula:

C14H26O2

IUPAC Name:

2,4,7,9-tetramethyldec-5-yne-4,7-diol

Details on test material:

100 % purity
Batch number: 407068

Method

Species / strain

Species / strain / cell type:

mouse lymphoma L5178Y cells

Details on mammalian cell type (if applicable):

- Type and identity of media:
- Periodically "cleansed" against high spontaneous background: yes

Metabolic activation:

with and without

Metabolic activation system:

S9

Test concentrations with justification for top dose:

8.83 to 2260 µg/ml

Vehicle / solvent:

- Vehicle(s)/solvent(s) used: DMSO;

Controls

Untreated negative controls:

no

Negative solvent / vehicle controls:

yes

Positive controls:

yes

Positive control substance:

ethylmethanesulphonate

Remarks:

Migrated to IUCLID6: ethylmethanesulphonate in in the absence of of metabolic activation; cyclophosphamide in the presence of metabolic activation

Results and discussion

Test results

Species / strain:

mouse lymphoma L5178Y cells

Metabolic activation:

with and without

Genotoxicity:

negative

Cytotoxicity / choice of top concentrations:

not determined

Vehicle controls validity:

valid

Positive controls validity:

valid

Additional information on results:

Two independent experiments wre performed. In Experiment 1, L5178Y TK +/- 3.7.2c mouse lymphoma cells (heterozyous at the thymidine kinase locus) were treated with the test material at up to eight dose levels, in duplicate, together with vehicle (solvent) and positive controls using 4 -hour exposure groups both in the asence and presence of metabolic activation (2% S9). In experiment 2, the cells were treated with the test material at up to eight dose levels using a 4 -hour exposure group in the absence of metabolic activation.
The dose range of test material was selected following the results of a preliminary toxicity test and for the first experiment was 4.38 to 140 µg/ml in the absence of metabolic activation, and 17.5 to 280 µg/ml in the presence of metabolic activation. For the second experiment the dose range was 4.38 to 140 µg/ml in the absence of metabolic activation, and 17.5 to 210 µg/ml in the presence of metabolic activation.

Remarks on result:

other: all strains/cell types tested

Remarks:

Migrated from field 'Test system'.

Applicant's summary and conclusion

Conclusions:

Interpretation of results (migrated information):
negative non-mutagenic

The test material was considered to be non-mutagenic to L5178Y cells under the conditions of the test.

Executive summary:

Intoduction:

The study was conducted according to a method that was designed to assess the potential mutagenicity of the test material on the thymidine kinase, TK +/-, locus of the L5178Y mouse lymphoma cell line, >>The method used meets the requirements of the OECD (476) and the Method B17 of Commission Regulation (EC) No. 440/2008 of 30 May 2008.

Methods:

Two independent experiments wre performed. In Experiment 1, L5178Y TK +/- 3.7.2c mouse lymphoma cells (heterozyous at the thymidine kinase locus) were treated with the test material at up to eight dose levels, in duplicate, together with vehicle (solvent) and positive controls using 4 -hour exposure groups both in the asence and presence of metabolic activation (2% S9). In experiment 2, the cells were treated with the test material at up to eight dose levels using a 4 -hour exposure group in the absence of metabolic activation.

The dose range of test material was selected following the results of a preliminary toxicity test and for the first experiment was 4.38 to 140 µg/ml in the absence of metabolic activation, and 17.5 to 280 µg/ml in the presence of metabolic activation. For the second experiment the dose range was 4.38 to 140 µg/ml in the absence of metabolic activation, and 17.5 to 210 µg/ml in the presence of metabolic activation.

Results:

THe maximum dose level used in the mutagenicity test was limited by test material-induced toxicity. Precipitate of the test material was not observed at any of the dose levels in the mutagenicity test. The vehicle (solvent) controls had acceptable mutant frequency values that were within the normal range for the L5178Y cel line at the TK +/- locus. The positive control materials induced marked increases in the mutant frequency indicating the satisfactory perfomance of the test and of the activity of the metabolising system.

The test material did not induce any toxicologically significant dose-related increases in the mutant frequency at any dose level, either with or without metabolic activation, in either the first or the second experiment.

Conclusion:

The test material was considered to be non-mutagenic to L5178Y cells under the conditions of the test.